Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
September 22, 2025
Avalo Therapeutics, a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, announced the appointment of Kevin R. Lind to